Cure Forward, a New York City-based patient activation Company, secured $15m in Series A financing.
The investment was made by Apple Tree Partners.
The company intends to use the funds to create a multisided technology platform for healthcare built around the science and technology of precision medicine.
Led by Martin Naley, CEO, Cure Forward aims to leverage molecular science to connect patients with relevant information, treatment options, and other patients with similar characteristics.
It is currently in a private beta and will launch in September of 2015.